Incorporating parp-inhibitors in primary and recurrent ovarian cancer: a meta-analysis of 12 phase ii/iii randomized controlled trials

After almost 20 years of carboplatin plus paclitaxel upfront treatment for ovarian cancer [1,2], the new millennium started with the successful introduction of targeted-therapies into the management of advanced disease [3,4]. In 2011, the anti-angiogenetic monoclonal antibody Bevacizumab was the first to be incorporated into first-line management of advanced disease (EMA, December 2011). The second decade of 2000s is witnessing a new ovarian cancer paradigm shift based on the results recently obtained in first line setting by a new categories of targeted agents: the Poly (ADP-ribose) polymerase (PARP)-Inhibitors (PARPi) [5 –8].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Systematic or Meta-analysis Studies Source Type: research